Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 vs Everolimus in Refractory Renal Cell Carcinoma
NCT01239342Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2011
- Primary completion
- Sep 2018
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206 in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Jan 2011; status: terminated.
02
Drugs
MK-2206
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01239342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01239342.